SXR8 Review (2026): iShares Core S&P 500 UCITS ETF

Disclosure and disclaimer. This article contains affiliate links to brokers. If you open an account through one we may earn a commission at no extra cost to you. Editorial decisions are independent — see our full affiliate disclosure. Nothing here is financial, tax, or legal advice; read our investment disclaimer before acting on anything you read. Past performance does not predict future results. For decisions involving tax, country-specific rules, or your personal circumstances, consult a regulated advisor in your country of residence.

Ask any European beginner which ETF to buy "for the S&P 500" and nine times out of ten the answer comes back: SXR8. It is the default S&P 500 UCITS in German-speaking Europe, one of the two tied-cheapest S&P 500 trackers available to EU retail investors, and one of the largest UCITS ETFs in existence — roughly €95 billion in assets per Lightyear's compare tool. That kind of scale is not an accident. It is also not, on its own, a reason to buy.

This review does for SXR8 what our IWDA review and VWCE review did for those funds: walk through the real facts, the two comparison battles that matter (SXR8 vs IWDA for the S&P-vs-MSCI-World debate, SXR8 vs VUAA for the tied-TER same-index rivalry), the tech-concentration risk you are accepting when you buy this fund, country tax, where to buy, and who should and should not own it.

No price predictions. No cheerleading about how the S&P 500 "always goes up". Just the factsheet, the trade-offs, and the honest concentration-risk discussion most competitor reviews gloss over.

TL;DR — what SXR8 is, in one paragraph

SXR8 is the Xetra ticker for the iShares Core S&P 500 UCITS ETF USD (Acc), ISIN IE00B5BMR087. It holds all 500 constituents of the S&P 500 — US large-cap stocks only — with a total expense ratio of 0.07% per year, tied for cheapest among S&P 500 UCITS trackers alongside VUAA. It is Ireland-domiciled, accumulates dividends internally (no cash payout), uses full physical replication, and is one of the largest UCITS equity ETFs in Europe with assets around €95 billion. The single-fund case is real if you specifically want a concentrated US-large-cap bet. It is not a diversification play — S&P 500 is a single-country index with heavy top-10 tech concentration. That is a feature if that is what you want to own, and a bug if you thought you were buying "the world".

Not financial advice. This is descriptive, not a recommendation. Past performance does not predict future results. Read the Key Information Document and confirm current TER, AUM and tracking difference on the iShares UK product page or JustETF before you act.

Fund facts — the hard data

Captured from the iShares UK product page, the JustETF profile and Lightyear's SXR8 vs VUAA compare on 2026-04-19.

Field	Value
Full name	iShares Core S&P 500 UCITS ETF USD (Acc)
ISIN	IE00B5BMR087
Ticker (Xetra, EUR)	SXR8
Ticker (London Stock Exchange, USD)	CSPX
Ticker (Borsa Italiana, EUR)	CSSPX
Ticker (SIX Swiss, CHF)	CSSPX
TER	0.07%
Distribution policy	Accumulating (ACC)
Domicile	Ireland
Base currency	USD
Fund launch	19 May 2010
Index tracked	S&P 500 (Net TR USD)
Replication method	Physical — full replication
Holdings	500
Fund AUM (all share classes)	~€95 billion
Issuer	BlackRock Asset Management Ireland
KID available	Yes (PRIIPs-compliant)

Methodology note. All figures above were verified against the iShares UK product page, JustETF and Lightyear on 2026-04-19. AUM fluctuates weekly and TER is reviewed by the issuer periodically. Always re-check on the issuer or JustETF profile before investing.

SXR8, CSPX and IUSA — killing the ticker confusion

The single most common question on Reddit about SXR8 goes "wait, is CSPX the same fund?" The answer is yes for CSPX, no for IUSA.

Ticker	Listing	Currency	ISIN	Distribution
SXR8	Xetra / Borsa Italiana	EUR	IE00B5BMR087	Accumulating
CSPX	London Stock Exchange	USD	IE00B5BMR087	Accumulating
CSSPX	Borsa Italiana / SIX Swiss	EUR / CHF	IE00B5BMR087	Accumulating
IUSA	LSE / AEX	USD / EUR	IE0031442068	Distributing

SXR8 and CSPX are the same fund in different quote currencies on different exchanges — same ISIN, same portfolio, same manager, same 0.07% TER. Pick whichever your broker lists commission-free in your deposit currency.

IUSA is a different fund. It is the distributing sibling: same S&P 500 index, same iShares issuer, but a separate UCITS share class that pays dividends out quarterly rather than reinvesting them. Different ISIN (IE0031442068), different TER (0.07% as well, verify on JustETF), different accumulation mechanic. If you want cash dividends from S&P 500 exposure, IUSA (or Vanguard's VUSA) is your route. For context on when to choose each, read our accumulating vs distributing ETFs pillar.

What's inside SXR8 — the 500 US large-caps

SXR8 tracks the S&P 500, which is market-cap weighted and rebalanced quarterly. As of early 2026, using data from the iShares UK product page and Yahoo Finance SXR8.DE:

Geography: 100% United States — this is the whole point. S&P 500 is US large-cap only. Every developed-market European investor who buys SXR8 is consciously (or unconsciously) making a single-country bet.

Top 10 holdings (~30-32% of the fund as of early 2026):

NVIDIA (~7%), Microsoft (~6.5%), Apple (~6%), Amazon (~3.5%), Alphabet Class A+C combined (~3.5%), Meta Platforms (~2.5%), Broadcom (~2%), Berkshire Hathaway (~1.5%), Eli Lilly (~1.5%), Tesla (~1.5%). Numbers shift daily; confirm on the iShares factsheet before relying on them.

Sector tilt (approximate): ~32% Technology, ~13% Financials, ~11% Health Care, ~10% Consumer Discretionary, ~9% Communication Services, with the rest across Industrials, Consumer Staples, Energy, Materials, Utilities and Real Estate.

Three things to flag:

1. Top-10 concentration ~30%. One dollar in three sits in the ten largest companies. That is structural: market-cap weighting with mega-cap dominance.
2. Tech / AI concentration. Add NVIDIA + Microsoft + Apple + Amazon + Alphabet + Meta + Broadcom — that is roughly 30% of the fund in companies whose valuations lean on the AI narrative. When the narrative wobbles, SXR8 wobbles harder than MSCI World.
3. No diversifier. No emerging markets, no developed-non-US, no bonds, no small-cap (S&P 500 is large-cap only). It is an intentionally narrow wrapper.

The S&P-vs-World debate — SXR8 vs IWDA

This is THE question for European investors considering SXR8: is it better than holding IWDA (MSCI World, developed markets)? The Lightyear IWDA vs SXR8 compare lays out the raw numbers; here is the full decision matrix.

Attribute	SXR8	IWDA
Issuer	BlackRock (iShares)	BlackRock (iShares)
Index	S&P 500	MSCI World
Coverage	US large-cap only (500 stocks)	23 developed markets (~1,500 stocks)
US weight	100%	~70%
Emerging markets?	No	No
TER	0.07%	0.20%
AUM (all share classes)	~€95B	~€110-115B
Distribution policy	Accumulating	Accumulating
Domicile	Ireland	Ireland
Replication	Physical — full replication	Physical — optimised sampling
Launch date	19 May 2010	25 September 2009
Top-10 concentration	~30%	~25%
Commonly paired with	Nothing (concentrated bet)	EIMI (for EM)

How to read this table. SXR8 is cheaper (13 bps lower TER — real money over decades on a large portfolio) but dramatically more concentrated. IWDA is more diversified but still ~70% US via the MSCI World weighting, so it is only partially a diversifier against SXR8-style concentration. A Reddit commenter on r/eupersonalfinance put this well: "if unforeseen events occur to SXR8, the same unforeseen events will occur to around 70% of IWDA (that's how much its US weight is)."

Why pick SXR8 over IWDA

• You explicitly want US-only exposure (for tax-loss-harvesting overlay, home-country tilt against your non-US equities, or a conviction-based active bet on US mega-cap).
• You are younger and comfortable with a concentrated equity bet because your human-capital and labour income diversify you elsewhere.
• You plan to pair SXR8 with a separate non-US developed ETF (e.g., a MSCI EAFE tracker) and an EM tracker to reconstruct your own global portfolio — possible, but ~usually not worth the complexity vs just buying IWDA. Reconstructing MSCI World with SXR8 + SPDR MSCI World ex-US + EIMI saves 1-3 basis points in blended TER at the cost of three trade tickets, three rebalancing decisions, and three tax lots. The simpler single-fund alternative wins for most people.

Why pick IWDA over SXR8

• You want developed-market diversification in one line.
• You do not want to make an active US-only bet.
• You plan to pair with EIMI for emerging markets — the canonical IWDA + EIMI two-fund portfolio sits at ~88/12 developed/EM weights.

The honest conclusion: SXR8 beat IWDA on returns over the last decade because US mega-cap tech ran. That is not a structural guarantee. Curvo's SXR8 vs IWDA vs VWCE backtest shows the historical data — but the 2010-2024 window is dominated by a US bull run; longer time series (1970-2010) show far tighter outcomes, with international developed markets leading in some decades. Past performance does not predict future results.

SXR8 vs VUAA — the tied-TER rivalry

Both SXR8 and VUAA track the S&P 500, both are Ireland-domiciled UCITS, both are accumulating, and both charge 0.07% TER. So which do you pick?

Attribute	SXR8	VUAA
Issuer	BlackRock (iShares)	Vanguard
Index	S&P 500	S&P 500
TER	0.07%	0.07%
AUM (all share classes)	~€95B	~€19B
Distribution policy	Accumulating	Accumulating
Domicile	Ireland	Ireland
Replication	Full physical	Full physical
ISIN	IE00B5BMR087	IE00BFMXXD54
Launch date	19 May 2010	14 May 2019
Approx share price (2026)	~€632	~€113

The practical decision comes down to three factors:

1. Broker availability. Whichever your broker lists commission-free in your deposit currency wins by default. Both are on Trading 212, DeGiro, Interactive Brokers and Lightyear, but specific exchange/commission-free coverage varies.
2. Liquidity. SXR8 is about 5x larger than VUAA per Lightyear's compare. On realistic retail ticket sizes this is noise — both trade with tight spreads. A Reddit r/eupersonalfinance SXR8 or VUAA? thread reaches the same conclusion.
3. Share price and cash drag. This is the subtle one. At ~€632 per share, SXR8 is a chunky unit; if you contribute €200/month on a non-fractional broker like DeGiro, you have to wait 4 months to buy a single share. VUAA at ~€113 is far friendlier for small monthly DCA — three shares per €350 contribution. On fractional-share brokers like Trading 212 or Lightyear this does not matter.

Which should you pick? Usually SXR8 if your broker offers it commission-free and you are not constrained by share price. VUAA if you are DCAing small amounts on a non-fractional broker. Functionally equivalent for long-term holders.

How "accumulating" actually works

Same mechanic as VWCE and IWDA. When SXR8's underlying companies pay dividends, those dividends are received by the fund, not by you. BlackRock reinvests them inside the fund, buying more index constituents. NAV grows; share count stays constant; each share becomes worth slightly more. You never see a dividend cash line on your broker statement; compounding happens inside the fund at zero execution cost.

This is tax-efficient in most EU jurisdictions but not all — Belgium's transaction tax, Germany's Vorabpauschale and Ireland's 8-year deemed disposal all create real friction. Country-by-country mechanics in our accumulating vs distributing ETFs pillar.

Tech concentration risk — the thing most reviews gloss over

A diligent review has to name this clearly. SXR8 is not "500 stocks, diversified" in any meaningful sense. Market-cap weighting means:

• The top 10 holdings are ~30% of the fund.
• The top 25 holdings (mostly tech + AI + large-cap growth) are ~40-45%.
• Technology sector alone is ~32% of the fund.
• Roughly 30% of SXR8 sits in seven AI-era mega-caps: NVIDIA, Microsoft, Apple, Amazon, Alphabet, Meta, Broadcom.

What this means in practice: SXR8 is more leveraged to AI-narrative sentiment than to "the US economy" in aggregate. When the Magnificent 7 sold off ~20% in a single month during risk-off periods in 2022 and 2025, SXR8 fell in near lock-step. A diversified MSCI World ETF like IWDA at ~70% US cushioned that move by ~30% simply because the rest of the world held up. That is not a prediction — US mega-cap tech could easily continue outperforming for another decade. It is a risk disclosure.

Academic work on concentration premia (including factor research published by AQR and available through the S&P Global methodology pages) discusses the historical norm: the top-10 US concentration today is near multi-decade highs, and mean-reversion on that measure is a known market regularity. It is not forecastable; it is simply a risk to size consciously.

Past performance does not predict future results. If you cannot stomach a 30-40% drawdown in an AI-narrative unwind, SXR8 is the wrong fund for your risk tolerance.

Historical performance — what the data shows

Per Morningstar and JustETF, SXR8 has delivered roughly 13-14% annualised since its May 2010 inception in USD terms — benefiting from one of the strongest US bull markets in modern history. Curvo's SXR8 vs IWDA vs VWCE backtest lets you compare the three directly.

Three caveats that matter.

1. Past performance does not predict future results — the 2010-2024 window was dominated by US mega-cap tech, exactly SXR8's overweight. Decades before and after may look nothing like this.
2. Returns are index-level, not investor-level — FX, buy-in sequence and trading costs shift your realised return.
3. Since-inception numbers start at the post-GFC bottom (May 2010), which flatters the annualised number by anchoring to a market trough.

Country tax brief — six European jurisdictions

A summary, not advice. Country tax rules change; consult a regulated advisor in your country of residence.

• Germany. Gains taxed via Vorabpauschale; Teilfreistellung shields 30% of equity-fund income. SXR8 qualifies — broadly tax-efficient.
• Netherlands. Box 3 on wealth (fictitious return). SXR8's accumulating structure does not materially affect Box 3 treatment. Check current methodology with the Belastingdienst — under reform.
• Belgium. 1.32% TOB on every buy and sell of accumulating Ireland-domiciled ETFs (includes SXR8). No tax on accumulated dividends within the fund. See Curvo's Best S&P 500 ETFs for Belgians 2026.
• Ireland. 41% exit tax on gains; 8-year deemed disposal crystallises tax even without sale — see Revenue.ie.
• UK. SXR8 / CSPX hold UK reporting fund status (verify on HMRC register). ISA and SIPP wrappers shelter gains entirely.
• France. Outside a PEA, SXR8 sits in a CTO — 30% flat PFU on realisation. ACC defers tax until sale.

SXR8-specific tax note. Because SXR8 holds 100% US stocks, the 15% US dividend withholding treaty benefit from Ireland-domicile is more valuable here than for IWDA (which is "only" ~70% US). An Ireland-domiciled S&P 500 UCITS saves roughly 15 percentage points of withholding versus an equivalent US-domiciled fund subject to the 30% default rate — one of the structural reasons European investors use UCITS wrappers at all.

Full walk-through: our accumulating vs distributing pillar.

Where to buy SXR8

SXR8 (and its LSE/USD sibling CSPX) is on the shelf at every major European broker. Most common routes:

• Trading 212 ([#affiliate-trading212]) — Commission-free on most European exchanges, fractional shares (so the ~€632 share price is not a problem), recurring AutoInvest with Pies for DCA. The path of least resistance for a first SXR8 purchase.
• DeGiro ([#affiliate-degiro]) — DeGiro explicitly lists the iShares Core S&P 500 UCITS ETF Acc among its Most Traded S&P 500 ETFs. No fractional shares. DeGiro's ETF Core Selection includes one free trade per month per Core ETF above a minimum size. If you are DCAing small amounts, VUAA's lower share price may fit DeGiro better than SXR8.
• Interactive Brokers ([#affiliate-ibkr]) — Cheapest on larger volume, great for professionals and lump-sum investors. Steeper UX. Tiered pricing.
• Lightyear ([#affiliate-lightyear]) — Newer EU broker with commission-free ETFs, fractional support, clean UX. SXR8 accessible on Xetra.

We compared two of these in detail: Trading 212 vs DeGiro. If you are starting from scratch — broker, KYC, first order — our how-to-start-investing-in-ETFs-as-a-European pillar walks through the whole sequence.

Risks and honest weaknesses

Five real risks a diligent review has to name:

1. Single-country (US) concentration. 100% of SXR8 is US equity. If US underperforms the rest of the developed world for a decade (as it did 2000-2010), SXR8 gives up far more than a globally diversified fund.
2. Top-10 and sector concentration. ~30% of the fund in ten companies, ~32% in technology. AI-narrative wobbles hit this fund disproportionately.
3. Currency exposure. Underlying assets are priced in USD. For a EUR-based investor, SXR8 returns include USD/EUR moves — sometimes a headwind.
4. No bonds / no diversifier. 100% equities. In a drawdown year can fall 30-40% with the market. Add a bond sleeve via the three-fund portfolio pillar.
5. Single-issuer risk. All of your S&P 500 exposure sits with BlackRock Asset Management Ireland. Operational risk low but non-zero.

Pros and cons

Pros.

• Ultra-low TER (0.07%) — tied-cheapest for S&P 500 UCITS.
• Accumulating = zero-friction compounding in most EU jurisdictions.
• Ireland-domiciled = 15% US dividend withholding via treaty (especially valuable given 100% US holdings).
• Enormous AUM (~€95B across share classes) — one of the largest and most liquid UCITS ETFs.
• iShares / BlackRock is a reputable issuer with deep ETF operational experience.
• Multiple exchange listings (SXR8, CSPX, CSSPX) with commission-free routes on most European brokers.
• Full physical replication (not sampling) — lower structural tracking error vs sampled funds.

Cons.

• 100% US concentration — single-country bet.
• Top-10 holdings ~30% of fund; tech sector ~32%.
• No emerging-market exposure.
• No developed-non-US exposure (Japan, Europe, Canada all absent).
• No bonds or small-caps.
• Share price ~€632 makes small monthly DCA awkward on non-fractional brokers.
• Belgium 1.32% TOB applies on every buy/sell.

Who should buy SXR8

SXR8 is a good fit — descriptive, not a recommendation — if most of these apply:

• 10+ year horizon and can stomach 30-40% drawdowns without panic selling.
• You explicitly want a concentrated US large-cap bet (and understand why).
• You plan to pair SXR8 with other ETFs (EIMI for EM, a developed-non-US tracker) as part of a multi-fund portfolio.
• You use SXR8 as a tilt within a wider portfolio rather than as your whole-market exposure.
• You are comfortable with AI/tech narrative risk concentrated in the top 10 holdings.
• You live in a country where accumulating funds are tax-neutral or efficient (DE, FR outside PEA, NL inside Box 3, UK inside ISA or SIPP).

Confirm the current TER and AUM on JustETF, read the KID, and when in doubt speak to a regulated advisor.

Who should NOT buy SXR8

SXR8 is a poor fit if:

• You want diversification. S&P 500 is a single-country, single-style bet. IWDA is the more-diversified developed-markets answer; VWCE is the one-fund all-world answer. Buy one of those instead.
• You want emerging markets. SXR8 has zero. Pair with EIMI or pick VWCE.
• You are close to retirement with no bonds. 100% equity + 100% US is an aggressive mix. Add bonds via the three-fund portfolio pillar.
• You want income. SXR8 is accumulating — no dividend cash. Use IUSA or VUSA for distributing S&P 500 UCITS exposure.
• You DCA small amounts on non-fractional brokers. SXR8's ~€632 share price creates cash drag. VUAA at ~€113 is friendlier.
• You thought you were buying "the whole US stock market". SXR8 is large-cap only. For total-market US exposure, look at Vanguard VUAG or other CRSP Total Market trackers.
• You can't resist tinkering. If seeing your single-fund drop 40% would make you sell, diversification is a behavioural tool. Buy IWDA or VWCE.

How SXR8 fits a complete portfolio

SXR8 is rarely the whole portfolio. The most common European setups using SXR8:

• SXR8 alone — a conviction US-large-cap bet. Works for investors who already have non-US exposure elsewhere (pension, employer equity, home-country fund).
• SXR8 + SPDR MSCI World ex-US + EIMI — the DIY three-fund that reconstructs a global portfolio with a US tilt. Costs: three trade tickets per rebalance. Usually not worth the complexity vs just buying IWDA (see best UCITS ETFs for beginners 2026 for the tiered view).
• SXR8 as a tilt — e.g., 70% IWDA + 30% SXR8 — overweights US mega-cap on top of a MSCI World base. Active call on US concentration.
• SXR8 + AGGH — 70/30 stock/bond using S&P 500 as the equity sleeve. More aggressive than IWDA + AGGH. Detailed in the three-fund portfolio pillar.

If you are not sure how to wire any of this up — broker choice, KYC, first order, recurring contributions — start with our step-by-step how-to-start-investing-in-ETFs-as-a-European guide.

Bottom line

SXR8 is a brilliant tool for a specific job — ultra-low-cost concentrated US large-cap exposure in an Ireland-domiciled UCITS wrapper. It is not, despite what the forum lore sometimes suggests, "the same as IWDA but cheaper". It is a different fund with a different risk profile: single-country, single-style, heavily top-10 concentrated.

The SXR8-vs-IWDA decision is not about "better". It is about whether you want a 100% US concentrated bet or a 70% US diversified one. Both have their place. For most new European investors a MSCI World-based fund like IWDA or an all-world fund like VWCE is a safer default because you do not need to have a view on US mean-reversion to buy them. SXR8 rewards investors who consciously want that concentrated bet and can stomach its drawdowns.

Either way: confirm numbers on JustETF, match yourself against the lists above, and talk to a regulated advisor if tax or personal circumstances are at stake.

Disclaimer (repeated). Nothing in this article is financial, tax, or legal advice. All figures were verified on 2026-04-19 against the iShares UK product page, JustETF's IE00B5BMR087 profile, Morningstar and Lightyear compare tools. ETF data changes; re-check before you act. Past performance does not predict future results. For country-specific or personal-circumstance decisions, consult a regulated advisor in your country of residence.